First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

[1]  C. Terkelsen,et al.  Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.

[2]  R. Ferrari,et al.  Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). , 2013, European heart journal.

[3]  H. Bezerra,et al.  Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study. , 2012, The Journal of invasive cardiology.

[4]  A. Tzafriri,et al.  Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Soo-Jin Kang,et al.  In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.

[6]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[7]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[8]  J. Ormiston,et al.  Stent thrombosis: has the firestorm been extinguished? , 2012, The Lancet.

[9]  C. Terkelsen,et al.  Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.

[10]  Y. Hayashi,et al.  Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2012, Circulation.

[11]  F. Eberli,et al.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.

[12]  S. de Servi,et al.  Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  John A Ormiston,et al.  Stent longitudinal integrity bench insights into a clinical problem. , 2011, JACC. Cardiovascular interventions.

[14]  M. Leon,et al.  Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. , 2011, JACC. Cardiovascular interventions.

[15]  T. Stijnen,et al.  Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  Gregg W Stone,et al.  Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.

[17]  F. Eberli,et al.  Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.

[18]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[19]  R. Virmani,et al.  Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. , 2011, Journal of the American College of Cardiology.

[20]  R. Virmani.  Evolving DES Platforms , 2010 .

[21]  P. Fitzgerald,et al.  Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent With the TAXUS Liberté Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions , 2010, Circulation. Cardiovascular interventions.

[22]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[23]  Xin-gang Wang,et al.  Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model. , 2009, International heart journal.

[24]  Patrick W Serruys,et al.  Reproducibility of quantitative optical coherence tomography for stent analysis. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[26]  P. Fitzgerald,et al.  Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. , 2007, The American journal of cardiology.

[27]  A. Kaltoft,et al.  Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. , 2007, Journal of the American College of Cardiology.

[28]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[29]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[30]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[31]  Michael Joner,et al.  Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.

[32]  P. Fitzgerald,et al.  Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.

[33]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[34]  M. Briel,et al.  Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.

[35]  Matthew H Samore,et al.  Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.

[36]  C. Indolfi,et al.  Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). , 2005, The American journal of cardiology.

[37]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[38]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[39]  Giuseppe Biondi-Zoccai,et al.  Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. , 2012, JACC. Cardiovascular interventions.

[40]  B. Gersh.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .

[41]  M. Pfisterer,et al.  BASKET-LATE INVESTIGATORS, LATE CLINICAL EVENTS AFTER CLOPIDOGREL DISCONTINUATION MAY LIMIT THE BENEFIT OF DRUGELUTING STENTS: AN OBSERVATIONAL STUDY OF DRUG-ELUTING VERSUS BARE-METAL STENTS , 2006 .

[42]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .